PHLX Semiconductor Index posts best start to year on record, adding $5.7 trillion in market cap
Chip stocks are having a year that makes every other rally look quaint. The PHLX Semiconductor Index, the benchmark tracker of the 30 largest US-listed semiconductor companies, has posted its strongest start to any calendar year on record, with gains between 78% and 82% year-to-date as of late May.
To put that in perspective, the companies in the index have collectively added roughly $5.7 trillion in market capitalization since January.
A record that stood for three decades just got demolished
The previous best opening stretch for the SOX was set in 1995, when the index gained 62% over its first 100 trading days. That benchmark survived the dot-com boom, the post-financial-crisis recovery, and the initial AI hype wave of 2023-2024. It did not survive 2026.
The current rally has featured winning streaks of 14 to 17 consecutive sessions at various points this year. The index blew past the 10,000-point level and later cleared 12,000. For context, the SOX delivered a total return of 43.5% in 2025, outperforming the S&P 500 by 26 percentage points.
The individual performances are staggering
Sandisk has surged 570% year-to-date. Intel has more than tripled. AMD has grown large enough to surpass JPMorgan Chase in market capitalization.
The SOX includes heavyweights like Nvidia, Broadcom, Advanced Micro Devices, Micron Technology, Intel, Taiwan Semiconductor Manufacturing Company, and ASML. The common thread is AI-driven demand, with ongoing shortages in memory supplies adding fuel and creating pricing power for companies like Micron and Sandisk.
What this means for investors
The bear case deserves serious attention at these valuations. An 80% move in five months prices in a lot of future growth. When AMD is worth more than the largest US bank, the market is making aggressive assumptions about earnings trajectories.
For crypto-focused investors specifically, it’s worth noting what this rally is not. The semiconductor surge is being driven almost entirely by AI infrastructure demand, not by cryptocurrency mining or blockchain-related activity.
The concentration risk is also something to watch. The SOX is a 30-stock index, and a handful of mega-cap names drive a disproportionate share of the index’s performance, which means diversification within the semiconductor sector is less than it appears on the surface.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion
The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.

Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight
Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.
Eli Lilly (LLY.US) "lowers its stance" and joins forces with former rival Hims (HIMS.US) to compete for the self-pay weight loss drug market
Eli Lilly is collaborating with Hims & Hers Health, leveraging the telehealth company’s large customer base to expand access to its blockbuster weight loss drugs and boost sales of medications, including its new oral weight loss drug Foundayo.

